IL17A and rheumatoid arthritis: In light of these data, it has been shown that digoxin’s immunomodulatory and anti-inflammatory outcomes in RA patients are potentially mediated by downregulating Th17 cell populations with a subsequent reduction of serum IL-23 and IL-17A levels.